S&P 500   3,966.20 (-3.00%)
DOW   31,833.87 (-2.51%)
QQQ   294.64 (-3.77%)
AAPL   142.23 (-4.70%)
MSFT   256.82 (-3.75%)
FB   195.21 (-3.66%)
GOOGL   2,253.91 (-3.24%)
AMZN   2,168.93 (-6.00%)
TSLA   715.92 (-6.00%)
NVDA   171.84 (-5.46%)
BABA   88.72 (-3.55%)
NIO   16.00 (-3.79%)
AMD   97.37 (-4.98%)
CGC   5.68 (-3.57%)
MU   71.15 (-4.47%)
T   20.45 (-0.58%)
GE   75.61 (-1.03%)
F   12.89 (-4.73%)
DIS   105.31 (-3.07%)
AMC   13.18 (+2.17%)
PFE   50.46 (-1.71%)
PYPL   78.07 (-2.11%)
NFLX   180.69 (-5.18%)
S&P 500   3,966.20 (-3.00%)
DOW   31,833.87 (-2.51%)
QQQ   294.64 (-3.77%)
AAPL   142.23 (-4.70%)
MSFT   256.82 (-3.75%)
FB   195.21 (-3.66%)
GOOGL   2,253.91 (-3.24%)
AMZN   2,168.93 (-6.00%)
TSLA   715.92 (-6.00%)
NVDA   171.84 (-5.46%)
BABA   88.72 (-3.55%)
NIO   16.00 (-3.79%)
AMD   97.37 (-4.98%)
CGC   5.68 (-3.57%)
MU   71.15 (-4.47%)
T   20.45 (-0.58%)
GE   75.61 (-1.03%)
F   12.89 (-4.73%)
DIS   105.31 (-3.07%)
AMC   13.18 (+2.17%)
PFE   50.46 (-1.71%)
PYPL   78.07 (-2.11%)
NFLX   180.69 (-5.18%)
S&P 500   3,966.20 (-3.00%)
DOW   31,833.87 (-2.51%)
QQQ   294.64 (-3.77%)
AAPL   142.23 (-4.70%)
MSFT   256.82 (-3.75%)
FB   195.21 (-3.66%)
GOOGL   2,253.91 (-3.24%)
AMZN   2,168.93 (-6.00%)
TSLA   715.92 (-6.00%)
NVDA   171.84 (-5.46%)
BABA   88.72 (-3.55%)
NIO   16.00 (-3.79%)
AMD   97.37 (-4.98%)
CGC   5.68 (-3.57%)
MU   71.15 (-4.47%)
T   20.45 (-0.58%)
GE   75.61 (-1.03%)
F   12.89 (-4.73%)
DIS   105.31 (-3.07%)
AMC   13.18 (+2.17%)
PFE   50.46 (-1.71%)
PYPL   78.07 (-2.11%)
NFLX   180.69 (-5.18%)
S&P 500   3,966.20 (-3.00%)
DOW   31,833.87 (-2.51%)
QQQ   294.64 (-3.77%)
AAPL   142.23 (-4.70%)
MSFT   256.82 (-3.75%)
FB   195.21 (-3.66%)
GOOGL   2,253.91 (-3.24%)
AMZN   2,168.93 (-6.00%)
TSLA   715.92 (-6.00%)
NVDA   171.84 (-5.46%)
BABA   88.72 (-3.55%)
NIO   16.00 (-3.79%)
AMD   97.37 (-4.98%)
CGC   5.68 (-3.57%)
MU   71.15 (-4.47%)
T   20.45 (-0.58%)
GE   75.61 (-1.03%)
F   12.89 (-4.73%)
DIS   105.31 (-3.07%)
AMC   13.18 (+2.17%)
PFE   50.46 (-1.71%)
PYPL   78.07 (-2.11%)
NFLX   180.69 (-5.18%)
NASDAQ:LGVN

Longeveron (LGVN) Stock Forecast, Price & News

$8.90
-0.22 (-2.41%)
(As of 05/18/2022 12:21 PM ET)
Add
Compare
Today's Range
$8.90
$9.26
50-Day Range
$5.94
$15.61
52-Week Range
$2.84
$45.00
Volume
2,563 shs
Average Volume
1.55 million shs
Market Capitalization
$186.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-2.02
30 days | 90 days | 365 days | Advanced Chart
Receive LGVN News and Ratings via Email

Sign-up to receive the latest news and ratings for Longeveron and its competitors with MarketBeat's FREE daily newsletter.

Longeveron logo

About Longeveron

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LGVN
Fax
N/A
Employees
18
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.31 million
Book Value
$1.79 per share

Profitability

Net Income
$-17.05 million
Net Margins
-1,341.85%
Pretax Margin
-1,305.13%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$186.10 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/13/2022
Today
5/18/2022
Next Earnings (Estimated)
8/12/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.87 out of 5 stars

Medical Sector

724th out of 1,426 stocks

Pharmaceutical Preparations Industry

343rd out of 680 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -













Longeveron (NASDAQ:LGVN) Frequently Asked Questions

Is Longeveron a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Longeveron in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Longeveron stock.
View analyst ratings for Longeveron
or view top-rated stocks.

Are investors shorting Longeveron?

Longeveron saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 315,100 shares, a drop of 52.2% from the April 15th total of 658,700 shares. Based on an average trading volume of 5,010,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 7.0% of the shares of the stock are short sold.
View Longeveron's Short Interest
.

When is Longeveron's next earnings date?

Longeveron is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Longeveron
.

How were Longeveron's earnings last quarter?

Longeveron Inc. (NASDAQ:LGVN) announced its earnings results on Friday, May, 13th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.04. Longeveron had a negative trailing twelve-month return on equity of 61.98% and a negative net margin of 1,341.85%. During the same period last year, the firm posted ($0.18) earnings per share.
View Longeveron's earnings history
.

What price target have analysts set for LGVN?

2 Wall Street analysts have issued 12 month price objectives for Longeveron's stock. Their forecasts range from $14.00 to $14.00. On average, they expect Longeveron's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 54.5% from the stock's current price.
View analysts' price targets for Longeveron
or view top-rated stocks among Wall Street analysts.

Who are Longeveron's key executives?
Longeveron's management team includes the following people:
When did Longeveron IPO?

(LGVN) raised $30 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 2,700,000 shares at $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. acted as the underwriters for the IPO.

What is Longeveron's stock symbol?

Longeveron trades on the NASDAQ under the ticker symbol "LGVN."

Who are Longeveron's major shareholders?

Longeveron's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.55%), Sassicaia Capital Advisers LLC (0.49%), Citigroup Inc. (0.35%), Gamco Investors INC. ET AL (0.16%), Gamco Investors INC. ET AL (0.16%) and Anson Funds Management LP (0.10%). Company insiders that own Longeveron stock include Geoff Green, James Clavijo, Joshua Hare, Paul T Lehr and Rock Soffer.
View institutional ownership trends for Longeveron
.

Which major investors are buying Longeveron stock?

LGVN stock was bought by a variety of institutional investors in the last quarter, including Sassicaia Capital Advisers LLC, Citigroup Inc., Gamco Investors INC. ET AL, Gamco Investors INC. ET AL, Anson Funds Management LP, and Vanguard Group Inc.. Company insiders that have bought Longeveron stock in the last two years include Geoff Green, James Clavijo, Joshua Hare, Paul T Lehr, and Rock Soffer.
View insider buying and selling activity for Longeveron
or or view top insider-buying stocks.

How do I buy shares of Longeveron?

Shares of LGVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Longeveron's stock price today?

One share of LGVN stock can currently be purchased for approximately $9.06.

How much money does Longeveron make?

Longeveron has a market capitalization of $189.44 million and generates $1.31 million in revenue each year. The company earns $-17.05 million in net income (profit) each year or ($0.88) on an earnings per share basis.

How many employees does Longeveron have?

Longeveron employs 18 workers across the globe.

What is Longeveron's official website?

The official website for Longeveron is www.longeveron.com.

How can I contact Longeveron?

Longeveron's mailing address is 1951 NW 7TH AVENUE SUITE 520, MIAMI FL, 33136. The company can be reached via phone at 305-909-0840 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.